68Ga-DOTATOC PET/CT检出肺泡软部肉瘤高表达生长抑素受体
一例肺泡软部肉瘤(ASPS)患者因怀疑胰腺神经内分泌肿瘤先后接受FDG-PET/CT与DOTATOC PET。DOTATOC PET示胰腺病灶无摄取,但原发肩胛骨ASPS及既往未识别的乳腺和颅骨转移灶呈高摄取,提示高表达生长抑素受体(SSTR)。此为首次报道ASPS的DOTATOC摄取,提示177Lu-DOTATATE靶向SSTR治疗的可能性。
要点
- ASPS可高表达生长抑素受体,DOTATOC PET可检出原发灶及隐匿转移。
- FDG-PET/CT后加做DOTATOC PET可改变ASPS分期与治疗思路。
- DOTATOC高摄取提示可考虑177Lu-DOTATATE靶向治疗。
核心结论
- ASPS可表现高SSTR表达,DOTATOC PET能显示原发灶及乳腺、颅骨转移,提示SSTR靶向治疗可行。
研究设计与样本
- 单例ASPS患者的个案报告,先后行FDG-PET/CT与DOTATOC PET/CT。
主要发现
- DOTATOC PET示胰腺病灶无摄取,原发肩胛骨ASPS及既往未识别的乳腺和颅骨转移灶呈高摄取。
临床怎么用
- ASPS患者可考虑DOTATOC PET评估SSTR表达,高摄取者或可尝试177Lu-DOTATATE治疗。
局限性
- 仅为单例个案报告,结论需更多病例验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A patient with alveolar soft part sarcoma (ASPS) underwent FDG-PET/CT followed by a DOTATOC PET due to a suspicion of a pancreatic neuroendocrine tumor. DOTATOC PET showed no uptake in the pancreatic lesion but revealed high uptake in the primary ASPS in scapula and previously unrecognized metastases in the breast and skull, indicating high somatostatin receptor (SSTR) expression. To our knowledge, this is the first report of DOTATOC uptake in ASPS, which raises the prospect of SSTR-targeted treatment with 177 Lu-DOTATATE.
引用
- Gregersen T, Rose HK, Bærentzen S, et al. High Somatostatin Receptor Expression in Alveolar Soft Part Sarcoma Detected by 68 Ga-DOTATOC PET/CT. Clin Nucl Med. 2026. PMID: 42257554. doi:10.1097/RLU.0000000000006329
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。